



US006630507B1

(12) **United States Patent**  
**Hampson et al.**

(10) **Patent No.:** **US 6,630,507 B1**  
(45) **Date of Patent:** **Oct. 7, 2003**

(54) **CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS**

(75) Inventors: **Aidan J. Hampson**, Irvine, CA (US);  
**Julius Axelrod**, Rockville, MD (US);  
**Maurizio Grimaldi**, Bethesda, MD (US)

(73) Assignee: **The United States of America as represented by the Department of Health and Human Services**, Washington, DC (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/674,028**

(22) PCT Filed: **Apr. 21, 1999**

(86) PCT No.: **PCT/US99/08769**

§ 371 (c)(1),  
(2), (4) Date: **Feb. 2, 2001**

(87) PCT Pub. No.: **WO99/53917**

PCT Pub. Date: **Oct. 28, 1999**

**Related U.S. Application Data**

(60) Provisional application No. 60/082,589, filed on Apr. 21, 1998, and provisional application No. 60/095,993, filed on Aug. 10, 1998.

(51) **Int. Cl.**<sup>7</sup> ..... **A61K 31/35**  
(52) **U.S. Cl.** ..... **514/454**  
(58) **Field of Search** ..... 514/454

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,304,669	A	12/1942	Adams	568/743
4,876,276	A	10/1989	Mechoulam et al.	514/454
5,227,537	A	7/1993	Stoss et al.	568/811
5,284,867	A	2/1994	Kloog et al.	514/454
5,434,295	A	7/1995	Mechoulam et al.	560/141
5,462,946	A	10/1995	Mitchell et al.	514/315
5,512,270	A	4/1996	Ghio et al.	424/45
5,521,215	A	5/1996	Mechoulam et al.	514/454
5,538,993	A	7/1996	Mechoulam et al.	514/454
5,635,530	A	6/1997	Mechoulam et al.	514/454
5,696,109	A	12/1997	Malfroy-Camine et al.	514/185
6,410,588	B1	6/2002	Feldmann et al.	514/454

**FOREIGN PATENT DOCUMENTS**

EP	427518	A1	5/1991
EP	576357	A1	12/1993
EP	656354	A1	6/1995
EP	658546	A1	6/1995
WO	WO9305031	A1	3/1993
WO	WO9412667	A1	6/1994
WO	WO9612485	A1	5/1996
WO	WO9618600	A1	6/1996
WO	WO9719063	A1	5/1997
WO	99/53917	*	10/1999

**OTHER PUBLICATIONS**

Windholz et al., *The Merck Index*, Tenth Edition (1983) p. 241, abstract No. 1723.\*  
 Mechoulam et al., "A Total Synthesis of d1-Δ<sup>1</sup>-Tetrahydrocannabinol, the Active Constituent of Hashish<sup>1</sup>," *Journal of the American Chemical Society*, 87:14:3273-3275 (1965).  
 Mechoulam et al., "Chemical Basis of Hashish Activity," *Science*, 18:611-612 (1970).  
 Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," *Acta Chem. Scand. B* 31, 9:807-812 (1977).  
 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients<sup>1</sup>," *Pharmacology*, 21:175-185 (1980).  
 Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," *Experimental Neurology*, Academic Press Inc., 70:626-637 (1980).  
 Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," *J. Clin. Pharmacol.*, 21:449S-463S (1981).  
 Carlini et al., "Hypnotic and Antiepileptic Effects of Cannabidiol," *J. Clin. Pharmacol.*, 21:417S-427S (1981).  
 Karler et al., "The Cannabinoids as Potential Antiepileptics," *J. Clin. Pharmacol.*, 21:437S-448S (1981).  
 Consroe et al., "Antiepileptic Potential of Cannabidiol Analogs," *J. Clin. Pharmacol.*, 21:428S-436S (1981).

(List continued on next page.)

*Primary Examiner*—Kevin E. Weddington  
(74) *Attorney, Agent, or Firm*—Klarquist Sparkman, LLP

(57) **ABSTRACT**

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH<sub>3</sub>, and COCH<sub>3</sub>.

(I)

